Biomedical Technology

Alephoson Biopharmaceuticals Limited

🌍 Official Website 🏢 HKSTP Source
45 Potential

Decision Maker

Dr. Benjamin LEE
blee@alephoson.com
+852 6737 2711
Unit 325, 3/F, Building 16W, No. 16 Science Park West Avenue, Hong Kong Science Park, Pak Shek Kok, Hong Kong
Raw Description
Alephoson Biopharmaceuticals Limited (AB) is a private, technology-based company focusing on research and development of innovative drug delivery technologies to fulfil unmet medical needs. By utilizing the destructive, and proprietary next generation Cell Penetration Protein Alternation Technology (CePPA), we are working to overcome the limitations of current treatments for serious ophthalmic diseases by developing a topical eye drop alternative to intravitreal (back-of-the eye) injection therapies. At AB, we understand the critical role vision plays in a patient’s quality of life, and we know the frustration that ophthalmologists face when they are unable to treat their patients successfully, and for patients and families for whom the burden of chronic treatment can be overwhelming. We are determined to develop new ocular therapies that help patients see their very best throughout their lives. Our management team and board of directors bring extensive experience discovering, evaluating, developing, and commercializing drugs. These novel therapies may include improvements to existing medicines or entirely new molecules.

Strategic Analysis

Executive Brief

Alephoson Biopharmaceuticals (AB) is a biotechnology firm specializing in non-invasive drug delivery systems for ophthalmic diseases. Their core innovation is the CePPA (Cell Penetration Protein Alternation Technology), designed to replace painful intravitreal injections with topical eye drops. Their work involves complex protein engineering and the development of delivery vehicles that can bypass biological barriers in the eye.

Strategic Fit & Lead Score

Lead Score: 45 (40-59: General Research / Engineering)

Why this Score? While Alephoson is primarily a drug-development company, their technical bottlenecks lie in protein characterization, high-sensitivity sensing, and micro-scale manufacturing of delivery systems. 6C’s Diamond Technology offers unique value in bio-analytical hardware and electrochemical sensing that can accelerate their R&D and drug-validation phases. Diamond is the most bio-compatible and chemically inert material known, making it a "sleeper" solution for pharmaceutical R&D labs.

6C Solutions Proposal

Application Area 6C Solution Technical Value Prop
Real-time Pharmacokinetics BDD Electrochemical Sensors Boron Doped Diamond (BDD) electrodes allow for real-time detection of drug concentration in ocular fluids. High sensitivity and resistant to "bio-fouling" (protein sticking).
Protein Analysis (CePPA) SCD Optical Windows / ATR Prisms Single Crystal Diamond (SCD) provides a wide transmission window (UV to Far-IR). Ideal for Infrared Spectroscopy to verify protein folding/stability in CePPA formulations.
Precision Formulation Diamond-Coated Microfluidics 6C can coat microfluidic channels in diamond, providing a zero-leach, chemically inert environment for synthesizing delicate protein-based drug carriers.
Ocular Diagnostic Tools Ultra-smooth PCD Optics For any accompanying diagnostic hardware, Polycrystalline Diamond (PCD) offers superior clarity and scratch resistance for imaging the "back-of-the-eye" through topical interfaces.

Engagement Hooks

  • Technical Question: "How are you currently monitoring the real-time diffusion rates of the CePPA molecules across the corneal barrier, and do you experience sensor drifting due to protein adhesion on your electrode surfaces?"
  • Value Statement: "6C's Boron Doped Diamond (BDD) electrodes provide the world's only 'non-stick' electrochemical surface, enabling Alephoson to achieve precise, continuous monitoring of drug delivery without the signal degradation common in standard gold or carbon sensors."